Do GLP-1 meds cause cancer?

Human data does not show that GLP-1 receptor agonists cause cancer. The FDA boxed warning for thyroid C-cell tumors is based on rat studies and the label states human relevance is undetermined.

Does GLP-1 cause colon cancer?

No. Large observational studies of GLP-1 agonists and colon cancer show reduced colorectal cancer incidence in GLP-1 users compared with patients on other diabetes drugs, not an increase.

Does GLP-1 increase the risk of cancer overall?

Pooled randomized trial data and large pharmacoepidemiology studies show no increased overall cancer risk and a possible reduction for several obesity-associated cancers.

What did SELECT find about cancer?

SELECT randomized 17,604 adults to semaglutide 2.4 mg or placebo for a mean of 39.8 months and reported no increased incidence of malignant neoplasms in the semaglutide arm.

Do incretin mimetics cause pancreatic cancer?

No. The FDA and EMA both reviewed the early pancreatic cancer concern and found insufficient evidence. Subsequent large meta-analyses have not shown an increase in pancreatic cancer with GLP-1 use.

Do GLP-1 medications cause breast cancer?

There is no boxed warning or labeling caution for breast cancer. Observational data does not show an increased breast cancer risk in GLP-1 users, and a Memorial Sloan Kettering study in 2025 supported feasibility in survivors.

Is GLP-1 safe for breast cancer survivors?

It can be, with oncology team coordination. A 2025 MSK study found GLP-1 drugs helped breast cancer patients lose weight without evidence of increased recurrence, though randomized data is still pending.

Can I take GLP-1 after cancer?

Often yes, depending on the cancer type, treatment phase, and personal medical history. A history of MTC or MEN 2 is an absolute contraindication. Other cancer histories require a case-by-case discussion.

Do GLP-1 agonists cause lymphoproliferative disorders in adults?

No signal for lymphoma or leukemia has emerged from cardiovascular outcome trials or pooled meta-analyses. Rates are comparable between GLP-1 and placebo or comparator arms.

Is the FDA going to remove the GLP-1 cancer warning?

There is no public indication that the FDA plans to remove the boxed warning for thyroid C-cell tumors. The contraindication for MTC and MEN 2 history remains in force.

Why does the boxed warning exist if humans do not get the cancer?

Rats develop dose-dependent thyroid C-cell tumors on chronic GLP-1 exposure. The FDA requires preclinical cancer signals to be communicated even when human relevance is undetermined.

Should I get my thyroid checked while taking a GLP-1?

Routine calcitonin screening is not recommended by the FDA because false positives are common in a low-risk population. New neck lumps, persistent hoarseness, or trouble swallowing warrant evaluation.

Does GLP-1 Cause Cancer? What the Evidence Actually Shows

Summary: Every GLP-1 receptor agonist on the US market carries an FDA boxed warning for thyroid C-cell tumors based on rat studies, but the large human trials and meta-analyses so far show a neutral or possibly protective cancer signal.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumors based on rat studies, and they are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1]^[2]^[4]. That warning is real and it is on every label. What it does not say is that GLP-1 drugs have been shown to cause cancer in humans. The human data, including the 17,604-patient SELECT trial and multiple large observational studies, has not turned up an increased cancer signal, and several large analyses point toward a neutral or possibly protective effect across most tumor types ^[3]^[5].

That is the full picture in one paragraph. The rest of this article unpacks the warning, the trial data, and what is and is not known for each major cancer type.

The FDA boxed warning, in plain language

Every GLP-1 receptor agonist approved in the United States carries the same boxed warning at the top of its label. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, and Victoza all share it. The exact wording from the Wegovy label reads: "In both genders of rats, semaglutide causes a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined." ^[2]

Two things to take from that. First, the warning is based on rodent data, not human data. Rats and mice have a much higher density of GLP-1 receptors on thyroid C cells than humans do, and they develop C-cell tumors when chronically exposed to GLP-1 agonists. Second, the label explicitly says human relevance is undetermined. The boxed warning exists because the FDA requires manufacturers to communicate any preclinical cancer signal in a class where humans will take the drug for years.

The contraindication is firm. If you have a personal or family history of MTC, or if you have MEN 2 (a hereditary syndrome that predisposes to MTC), you cannot take a GLP-1 receptor agonist. That is not a precaution. It is a hard "do not prescribe" line.

What human trials have actually shown

The largest cardiovascular outcome trials of GLP-1 receptor agonists collected cancer events as adverse events and reported them in the safety analyses. The signal across these trials is consistent: no statistically significant increase in cancer overall, no signal for thyroid cancer, and no signal for pancreatic cancer.

SELECT is the most cited of these. The trial randomized 17,604 adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes to weekly semaglutide 2.4 mg or placebo, with a mean follow-up of 39.8 months. The primary cardiovascular endpoint was met (20 percent reduction in MACE). Cancer events were tracked. The published safety summary in the New England Journal of Medicine reported no increased incidence of malignant neoplasms in the semaglutide arm compared with placebo ^[3]. That is the largest, longest, randomized data set in a non-diabetic population to date, and it found no cancer signal.

LEADER (liraglutide, 9,340 patients), SUSTAIN-6 (semaglutide, 3,297 patients), REWIND (dulaglutide, 9,901 patients), and SURPASS-CVOT (tirzepatide, 13,299 patients) tell the same story. Pooled across these trials, total malignancy rates were similar between GLP-1 and comparator arms, and no specific cancer type emerged as significantly elevated.

A 2026 review in Nature Reviews Clinical Oncology summarized the meta-analytic evidence: across pooled randomized data and large pharmacoepidemiology cohorts, GLP-1 receptor agonists do not show an increased risk of cancer overall and show consistent signals of reduced risk for several obesity-associated cancers, including colorectal, pancreatic, and endometrial cancer ^[5]. The authors call the safety signal "reassuring" while noting that follow-up is still limited for long-duration use in non-diabetic populations.

Thyroid cancer, specifically

The thyroid signal is the one people ask about first because it is the only one on the boxed warning. Here is what the human data shows.

Multiple observational studies have looked for an excess of thyroid cancer in GLP-1 users versus other glucose-lowering drug users. The results are mixed. A 2022 French nationwide study suggested a small increase in thyroid cancer risk in GLP-1 users (hazard ratio around 1.6 after one to three years of use), but the analysis was criticized for detection bias, because patients on GLP-1 drugs often get more imaging and lab work than those on older diabetes drugs, and thyroid nodules turn up incidentally.

The European Medicines Agency completed a formal review in 2023 covering exenatide, liraglutide, dulaglutide, lixisenatide, and semaglutide and concluded that the available evidence does not support a causal association between GLP-1 receptor agonist use and thyroid cancer. The 2026 Nature Reviews Clinical Oncology review reached the same conclusion based on pooled observational and randomized data.

The rat C-cell tumor effect appears to be species-specific. Human thyroid C cells express GLP-1 receptors at much lower density than rodent C cells, and human C cells do not proliferate in response to GLP-1 stimulation in the same way. That biological difference is the leading explanation for why the rodent signal has not translated to humans in the data collected so far.

What this does not mean: it does not mean the boxed warning will be removed. The FDA has not signaled any plan to remove it. The contraindication for personal or family history of MTC or MEN 2 remains absolute. If you have either, the drug is not for you.

Pancreatic cancer

Pancreatic cancer was the second early concern, dating to a 2013 case series that suggested an excess of pancreatic adverse events in patients on incretin-based therapies (GLP-1 agonists and DPP-4 inhibitors). The FDA and EMA both reviewed the data and found insufficient evidence to support a causal link.

Larger studies since then have been reassuring. A 2017 meta-analysis of 38 randomized trials covering more than 27,000 patient-years of exposure found no increase in pancreatic cancer with GLP-1 use. Pooled cardiovascular outcome trial data shows the same. The 2026 Nature Reviews Clinical Oncology review concluded that, if anything, long-term GLP-1 use is associated with a modest reduction in pancreatic cancer incidence in patients with type 2 diabetes ^[5].

Pancreatitis is a different question and not the topic of this article. GLP-1 receptor agonists do carry a warning for acute pancreatitis, which is a known but uncommon adverse effect. Acute pancreatitis is not pancreatic cancer.

Colorectal and other obesity-related cancers

Obesity is a known risk factor for at least 13 cancers, including post-menopausal breast, colorectal, endometrial, esophageal, gastric, hepatocellular, kidney, ovarian, pancreatic, thyroid (papillary), gallbladder, meningioma, and multiple myeloma. Because GLP-1 drugs produce substantial sustained weight loss, the expectation is that they should reduce the incidence of obesity-driven cancers over time.

A 2024 retrospective cohort study published in JAMA Network Open compared more than 1.6 million patients with type 2 diabetes treated with GLP-1 agonists versus insulin and found a significantly lower incidence of 10 of 13 obesity-associated cancers in the GLP-1 arm. Colorectal cancer showed one of the strongest reductions. A separate observational analysis of more than 170,000 people with diabetes and obesity found GLP-1 use was associated with reduced risk across 14 obesity-related cancers along with lower all-cause mortality.

For colorectal cancer specifically, a University of California Health analysis of more than 6,800 colorectal cancer patients found that those taking GLP-1 medications were less than half as likely to die within five years compared with patients not taking them. Observational data cannot prove causation, but the direction of effect across multiple independent cohorts is consistent.

Breast cancer and survivorship

GLP-1 receptor agonists are not contraindicated in patients with a history of breast cancer. There is no boxed warning or specific labeling caution related to breast cancer.

The clinical question that comes up most often is whether GLP-1 drugs are safe for breast cancer survivors who want to manage treatment-related weight gain. A Memorial Sloan Kettering study published in August 2025 found that breast cancer patients taking GLP-1 medications during or after treatment did lose weight, where they would otherwise typically gain it. Breast cancer recurrence and progression were not increased in this analysis. The researchers concluded the drugs appear to be a feasible weight management option for survivors, although they emphasized that randomized trial data is still needed.

Standard clinical practice for breast cancer survivors considering GLP-1 therapy is to discuss it with the oncology team, particularly for patients on active treatment. There is no blanket prohibition, but timing around chemotherapy or radiation matters because GI side effects can compound treatment toxicity.

Kidney cancer and other emerging signals

The Memorial Sloan Kettering patient information page notes that some research has found a small increased risk of kidney cancer in GLP-1 users. The signal is modest and not consistent across studies. It has not led to any change in labeling or any new contraindication. Patients with a personal history of kidney cancer should discuss it with their prescriber, but the evidence base does not currently support avoiding GLP-1 therapy on that basis alone.

There is no signal for lymphoproliferative disorders in adults from the cardiovascular outcome trials or the pooled meta-analyses. Lymphoma and leukemia rates in GLP-1 arms are comparable to placebo and comparator arms.

A 2025 study suggested a small increase in neuroendocrine tumor diagnoses in GLP-1 users, but the analysis was hypothesis-generating and the absolute event rates were very low. It has not changed prescribing guidance.

What about people who already had cancer?

The answer depends on the cancer and the treatment phase, and it is best decided with the oncology team. The general principles from the MD Anderson and Memorial Sloan Kettering patient guidance:

A history of MTC or MEN 2 is a hard contraindication. GLP-1 drugs are off the table.
Active chemotherapy is a relative caution. GI side effects from GLP-1 drugs can compound nausea and vomiting from chemo, and significant weight loss including muscle mass loss can make chemotherapy harder to tolerate.
Active pancreatic cancer is generally a caution because pancreatic cancer patients are already at elevated pancreatitis risk.
Stable survivors on long-term hormonal therapy (for example, breast cancer patients on aromatase inhibitors) have used GLP-1 drugs to manage treatment-related weight gain without evidence of increased recurrence risk in observational data.

The decision is not "GLP-1 versus cancer." It is a personalized risk-benefit conversation with the prescribing physician and the oncologist.

Will the FDA remove the boxed warning?

There is no indication that the FDA is moving to remove the C-cell tumor boxed warning. Some clinicians and researchers have argued that the warning is misleading because the rodent finding has not translated to humans after more than 15 years of widespread use. The counterargument is that the contraindication for MTC and MEN 2 is the load-bearing piece of the warning, the labeling reflects a real preclinical signal, and removing it would require a formal regulatory action backed by a definitive causal analysis.

For now, the warning stays. Prescribers screen for personal and family history of MTC and MEN 2 before initiation. Patients who pass that screen are prescribed the drug with the understanding that the rest of the cancer-related safety profile, based on the human evidence to date, is reassuring.

What this means for someone deciding whether to start

If you have no personal or family history of MTC or MEN 2, the cancer-related reasons not to take a GLP-1 receptor agonist are limited based on current evidence. The boxed warning is real, the contraindication is firm, and you should ask your prescriber about screening. Beyond that, the human data does not support the idea that GLP-1 drugs cause cancer, and the data is starting to suggest the opposite for several obesity-related malignancies.

What matters in your individual decision: a thorough medical history that captures any thyroid disease, MEN syndromes, pancreatitis history, and personal cancer history. A pre-treatment conversation about the boxed warning so you understand what it does and does not say. And realistic expectations about long-term use, because the cancer prevention benefit from weight loss only persists if the weight loss persists.

Common questions about GLP-1 and cancer risk

Do GLP-1 meds cause cancer?: Human data does not show that GLP-1 receptor agonists cause cancer. The FDA boxed warning for thyroid C-cell tumors is based on rat studies and the label states human relevance is undetermined.
Does GLP-1 cause colon cancer?: No. Large observational studies of GLP-1 agonists and colon cancer show reduced colorectal cancer incidence in GLP-1 users compared with patients on other diabetes drugs, not an increase.
Does GLP-1 increase the risk of cancer overall?: Pooled randomized trial data and large pharmacoepidemiology studies show no increased overall cancer risk and a possible reduction for several obesity-associated cancers.
What did SELECT find about cancer?: SELECT randomized 17,604 adults to semaglutide 2.4 mg or placebo for a mean of 39.8 months and reported no increased incidence of malignant neoplasms in the semaglutide arm.
Do incretin mimetics cause pancreatic cancer?: No. The FDA and EMA both reviewed the early pancreatic cancer concern and found insufficient evidence. Subsequent large meta-analyses have not shown an increase in pancreatic cancer with GLP-1 use.
Do GLP-1 medications cause breast cancer?: There is no boxed warning or labeling caution for breast cancer. Observational data does not show an increased breast cancer risk in GLP-1 users, and a Memorial Sloan Kettering study in 2025 supported feasibility in survivors.
Is GLP-1 safe for breast cancer survivors?: It can be, with oncology team coordination. A 2025 MSK study found GLP-1 drugs helped breast cancer patients lose weight without evidence of increased recurrence, though randomized data is still pending.
Can I take GLP-1 after cancer?: Often yes, depending on the cancer type, treatment phase, and personal medical history. A history of MTC or MEN 2 is an absolute contraindication. Other cancer histories require a case-by-case discussion.
Do GLP-1 agonists cause lymphoproliferative disorders in adults?: No signal for lymphoma or leukemia has emerged from cardiovascular outcome trials or pooled meta-analyses. Rates are comparable between GLP-1 and placebo or comparator arms.
Is the FDA going to remove the GLP-1 cancer warning?: There is no public indication that the FDA plans to remove the boxed warning for thyroid C-cell tumors. The contraindication for MTC and MEN 2 history remains in force.
Why does the boxed warning exist if humans do not get the cancer?: Rats develop dose-dependent thyroid C-cell tumors on chronic GLP-1 exposure. The FDA requires preclinical cancer signals to be communicated even when human relevance is undetermined.
Should I get my thyroid checked while taking a GLP-1?: Routine calcitonin screening is not recommended by the FDA because false positives are common in a low-risk population. New neck lumps, persistent hoarseness, or trouble swallowing warrant evaluation.

Where this leaves the question

GLP-1 receptor agonists carry a real boxed warning rooted in real rat data. They are contraindicated for a small, well-defined group of patients with MTC or MEN 2 history. For everyone else, the accumulated human evidence over more than 15 years of clinical use, including the largest randomized trial in a non-diabetic population (SELECT), points toward a neutral or favorable cancer safety profile, with growing observational evidence for protection against several obesity-driven cancers. The label captures the preclinical risk. The trial data captures the human reality. Both are true at the same time, and the prescribing decision lives at the intersection.